Abstract
Twelve type II diabetics were treated with gliclazide, a potent hypoglycaemic sulfonylurea, for 5 months. Plasma immunoreactive insulin (IRI), connecting peptide (C-peptide) and immunoreactive glucagon (IRG) were measured during a 2 h oral glucose tolerance test (OGTT) before and during gliclazide therapy. The OGTT improved in 7 patients. In those patients IRI concentrations were significantly more elevated during than before the treatment period. By contrast, gliclazide treatment did not affect the hepatic extraction of insulin (estimated by the molar ratio of C-peptide to IRI) nor the inappropriate glucagon release commonly observed in this type of patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
